Skip to main content
. 2024 Mar 20;16:1383278. doi: 10.3389/fnagi.2024.1383278

Table 5.

Results of evidence quality with GRADE.

Included studies Outcomes Risk of bias Inconsistency Indirectness Imprecision Publication bias Relative effect (95% CI) p-value Quality
Cheng and Wu (2016) PNTS (Watermeyer and Calia, 2019) −1 0 0 −1 −1 MD 16.30 (14.03,18.57) <0.0001 Very low
NPI (Kaur et al., 2019) −1 0 0 −1 −1 MD -6.42 (−8.87, −3.97) <0.0001 Very low
ADAS-cog (van der Kant et al., 2020) −1 0 0 −1 −1 MD −3.63 (−4.82, −2.45) <0.0001 Very low
Dong et al. (2018) ADAS-cog (Watermeyer and Calia, 2019) −1 0 0 −1 −1 MD −3.65 (−5.82, −1.48) 0.001 Very low
MMSE (Watermeyer and Calia, 2019) −1 0 0 0 −1 MD 0.49 (−1.45, 2.42) 0.61 Low
GDS scale (Kaur et al., 2019) −1 0 0 0 −1 MD −1.36 (−3.93, 1.21) 0.30 Low
CGIC scale (Kaur et al., 2019) −1 0 0 −1 −1 MD −0.79 (−1.24, −0.34) 0.0006 Very low
IADL scale (Kaur et al., 2019) −1 −1 0 −1 −1 MD 0.59 (−1.21, 2.38) 0.52 Very low
Liang et al. (2017) MMSE (van der Kant et al., 2020) −1 0 0 0 −1 MD 1.05 (0.21,1.88) 0.001 Low
ADAS-cog (Watermeyer and Calia, 2019) −1 0 0 0 −1 MD -0.71 (−1.04, −0.39) <0.0001 Low
Liao et al. (2015) MMSE (Silva et al., 2019) −1 0 0 0 −1 MD 1.00 (0.41, 1.58) 0.0008 Low
High frequency MMSE (Leng and Edison, 2021) −1 0 0 0 −1 MD 1.06 (0.47, 1.66) 0.0004 Low
Low frequency MMSE (Watermeyer and Calia, 2019) −1 0 0 0 −1 MD 0.97 (−0.62, 2.50) 0.24 Low
Lin et al. (2019) MMSE (Barker et al., 1985) −1 0 0 0 0 MD 0.60 (0.35, 0.85) <0.001 Moderate
Sing site MMSE (van der Kant et al., 2020) −1 0 0 −1 0 MD 0.13 (−0.35, 0.62) 0.60 Low
Multiple sites MMSE (Birks and Harvey, 2018) −1 0 0 0 0 MD 0.86 (0.18, 1.54) 0.01 Moderate
Short term treatment MMSE (van der Kant et al., 2020) −1 0 0 −1 −1 MD 0.29 (−1.04, 1.62) 0.67 Very low
Long term treatment MMSE (van der Kant et al., 2020) −1 0 0 0 −1 MD 2.77 (1.90, 2.92) <0.0001 Very low
Wang et al. (2020) MMSE (Pardo-Moreno et al., 2022) −1 0 0 0 −1 MD 0.42 (0.18, 0.67) 0.0006 Moderate
Sing site MMSE (van der Kant et al., 2020) −1 0 0 0 0 MD 0.24 (−0.45, 0.92) 0.50 Moderate
Multiple sites MMSE (van der Kant et al., 2020) −1 0 0 0 0 MD 0.47 (0.14, 0.79) 0.005 Moderate
Short term treatment MMSE (Braak et al., 2006) −1 0 0 0 −1 MD 0.18 (−0.20, 0.56) 0.36 Low
Long term treatment MMSE (Birks and Harvey, 2018) −1 0 0 0 −1 MD 0.59 (0.28, 0.90) 0.0002 Low
Xiu et al. (2024) MMSE (Pardo-Moreno et al., 2022) −1 0 0 0 0 MD 3.64 (1.86, 5.42) <0.0001 Moderate
Short term treatment MMSE (Kaur et al., 2019) −1 0 0 0 −1 MD 2.90 (−1.06, 6.86) 0.15 Low
Long term treatment MMSE (Watermeyer and Calia, 2019) −1 0 0 0 −1 MD 5.43 (2.84, 8.01) <0.0001 Low
MoCA (Silva et al., 2019) −1 0 0 0 −1 MD 3.69 (1.84, 5.54) <0.0001 Low
ADAS-cog (Silva et al., 2019) −1 0 0 0 −1 MD -3.53 (−4.91, −2.15) <0.0001 Low
P300 latency (Kaur et al., 2019) −1 −1 0 0 −1 MD −38.32 (−72.40, −4.24) 0.03 Very low
P300 amplitude (Kaur et al., 2019) −1 −1 0 0 −1 MD 1.09 (0.45, 1.72) <0.0001 Very low
Zhang et al. (2022) MMSE (Braak et al., 2006) −1 0 0 0 −1 MD 1.82 (1.41, 2.22) <0.0001 Low
ADAS-cog (Leng and Edison, 2021) −1 0 0 0 −1 MD 2.72 (1.77, 3.67) <0.0001 Low

PNTS, picture naming test score; NPI, neuropsychiatric inventory; ADAS-cog, Alzheimer disease assessment cognitive scale; MMSE, mini-mental state examination; IADL, instrumental daily living activity; GDS, geriatric depression scale; CGIC, clinician’s global impression of change.